While the individual cohort medians aren't separated out, the dose escalation is clearly making a difference. The median OS of the 1,200mg cohort is tracking somewhere around 22 months I'd think.
Two points -
- our median OS is vastly better than on 177 Lu-PSMA 617 alone
- the OS per cohort is extending with each dose escalation of idronoxil
Fantastic
Ann: Major Survival Benefit in Prostate Cancer Patients Announced, page-20
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.015(12.0%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 11.0¢ | $45.44K | 375.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 629029 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 84087 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |